Literature DB >> 12578150

Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon.

Tawanda Gumbo1, Roy F Chemaly, Carlos M Isada, Gerri S Hall, Steven M Gordon.   

Abstract

Complications occurring > 1 month after Candida glabrata fungemia have not been studied. We conducted a study to determine the frequency and morbidity of complications of C. glabrata bloodstream infections occurring > 1 month after infection. Late complications were common (incidence 9.9 per 100 patient years), and most often occurred within the first year. In a multivariate analysis, late complications were associated with the presence of diabetes mellitus [odds ratio (OR) 12.2; 95% confidence interval (CI) 1.2-130] and chronic renal failure (OR 14.7; 95% CI 1.2-184). These data suggest that careful long-term follow-up of patients with C. glabrata fungemia is important and present an opportunity to explore secondary prophylaxis.

Entities:  

Mesh:

Year:  2002        PMID: 12578150     DOI: 10.1080/0036554021000026936

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

1.  Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Robert W Kulawy; Christine Fregeau; Vasha Hsu; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Lei Ma; Mark R Deziel; Michael F Drusano; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

3.  Identification of Candida glabrata genes involved in pH modulation and modification of the phagosomal environment in macrophages.

Authors:  Lydia Kasper; Katja Seider; Franziska Gerwien; Stefanie Allert; Sascha Brunke; Tobias Schwarzmüller; Lauren Ames; Cristina Zubiria-Barrera; Michael K Mansour; Ulrike Becken; Dagmar Barz; Jatin M Vyas; Norbert Reiling; Albert Haas; Ken Haynes; Karl Kuchler; Bernhard Hube
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

4.  Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence.

Authors:  Ronen Ben-Ami; Offer Zimmerman; Talya Finn; Sharon Amit; Anna Novikov; Noa Wertheimer; Mor Lurie-Weinberger; Judith Berman
Journal:  MBio       Date:  2016-08-02       Impact factor: 7.867

5.  Anidulafungin in the treatment of invasive fungal infections.

Authors:  Kathryn Sabol; Tawanda Gumbo
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.